Key Highlights
- MetaVia (NASDAQ:MTVA) was trading up 23.85% at USD 1.35 on Friday, November 6, 2026, compared with a market Capitalization of about USD 9 million on a published data page. The data page showed a prior close of USD 1.09.
- A November 5 headline cited interim Phase 1 Part 3B data for DA-1726 with a statistically significant 68% reduction in liver fat, though full detail was not available.
- The stock's 52-week range runs from USD 0.966 to USD 13.42, so the shares trade about 90% below the high (calculated), reflecting heavy dilution and a reverse split.
- MetaVia's chief medical officer presented DA-1726 Phase 1 data on November 4, 2026 at the Precision Liver Symposium in Denver, as announced October 28.
Interim DA-1726 Liver Data Appears to Drive the Rally
MetaVia (NASDAQ:MTVA) was trading higher after a headline on November 5, 2026 described positive interim Phase 1 Part 3B data for DA-1726. That headline cited a statistically significant 68% reduction in liver fat, measured by MRI-PDFF. The full release could not be retrieved, so patient numbers, dose and comparison arms are unconfirmed. DA-1726 is an oxyntomodulin analogue that activates both GLP-1 and glucagon receptors, designed as a weekly injection for obesity and metabolic liver disease. The company had already announced on October 28 that Sarah Browne, its chief medical officer, would present the data on November 4. The timing suggests the move follows the readout, though no company statement confirms the cause.
Earlier Weight-Loss Readouts Frame the Expectations
Published headlines from earlier in 2026 reported that a 48 mg cohort reached up to 9.1% mean body weight reduction at Day 54 without a plateau, and the company has described the 32 mg dose as showing best-in-class potential. Those are company claims from small early trials, not head-to-head results against approved GLP-1 drugs. A Phase 1 liver-fat signal in a small group does not predict Phase 2 success. The company completed dose titration in its Phase 1 Part 3 obesity study in July. Investors typically weigh liver fat, weight loss, tolerability and lean mass together, and only some of those were visible in the available material.
Reverse Split History and a Funding Question
MetaVia's market capitalization was listed near USD 8.96 million at about USD 1.36 per share with 6.59 million shares outstanding, which is tiny for a clinical-stage developer. Shareholders approved a Reverse Stock Split at the 2026 annual meeting, and a published notice referenced a 1-for-11 split; the effective date was not confirmed here. The company's own risk language flags whether existing cash is sufficient, and no balance figure was found. With a share base this small, a financing could follow any rally. Quoted moves can reverse, and wide spreads are common. Volume was modest at about 768 thousand shares by midday on the data page, a small base for a 24.77% midday swing.
Where Things Stand
The surge appears tied to the November 5 interim DA-1726 data, but no company statement links it directly to the move. MetaVia (NASDAQ:MTVA) reported a 68% liver fat reduction in a headline, which gives the shares a catalyst, while the remaining detail and the funding position are unverified. A Market Value near USD 9 million means a few trades can move the price. The next markers are the full data release and poster, any reverse split mechanics and the third-quarter report.






Please wait processing your request...